Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat

46Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Chronic pain resulting from metastatic bone cancer remains poorly understood and resistant to treatment. Here we have examined the effect of the novel COX-2 enzyme inhibitor lumiracoxib in a model of bone cancer pain in the rat. Lumiracoxib was administered orally twice daily from day 10 to day 20 after injection of MRMT-1 tumour cells into one tibia. Mechanical hyperalgesia, measured as the reduction in weight-bearing of the ipsilateral limb, and the development of static and dynamic allodynia were significantly inhibited by repeated lumaricoxib administration. A similar reduction in hyperalgesia and allodynia was noted after twice daily administration of another COX-2 inhibitor, valdecoxib, whilst a single acute administration of either drug on day 20, produced no anti-nociceptive activity. Bone mineral density measurements, radiological scores and histological analysis showed that chronic lumaricoxib treatment also significantly attenuated bone destruction induced by tumour cell injection. These data indicate that lumiracoxib and other COX-2 inhibitors have potential therapeutic benefit in the treatment of bone cancer pain. © 2003 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

Figures

References Powered by Scopus

Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain

1492Citations
N/AReaders
Get full text

Malignant bone pain: Pathophysiology and treatment

793Citations
N/AReaders
Get full text

Breakthrough pain: Characteristics and impact in patients with cancer pain

645Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Models and mechanisms of hyperalgesia and allodynia

851Citations
N/AReaders
Get full text

Pain and nociception: Mechanisms of cancer-induced bone pain

270Citations
N/AReaders
Get full text

A rat model of bone cancer pain induced by intra-tibia inoculation of Walker 256 mammary gland carcinoma cells

146Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Fox, A., Medhurst, S., Courade, J. P., Glatt, M., Dawson, J., Urban, L., … Gonzalez, I. (2004). Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat. Pain, 107(1–2), 33–40. https://doi.org/10.1016/j.pain.2003.09.003

Readers over time

‘09‘10‘11‘12‘13‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘2402468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 13

57%

Professor / Associate Prof. 5

22%

Researcher 4

17%

Lecturer / Post doc 1

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 11

52%

Pharmacology, Toxicology and Pharmaceut... 4

19%

Agricultural and Biological Sciences 4

19%

Neuroscience 2

10%

Save time finding and organizing research with Mendeley

Sign up for free
0